Albertsons on Tuesday revised expectations for its annual identical sales, forecasting growth in a narrow band from flat to a 1% increase for fiscal 2026 - a projection that sits below the market consensus. Analysts polled by LSEG had averaged a 1.58% rise, a gap the company attributed to pressure on demand as larger rivals have stepped up discounting.
The firm described a retail environment in which persistently high inflation and broader economic uncertainty are prompting price-sensitive shoppers to cut back, even on staple purchases such as groceries. That pullback in consumer spending, combined with heightened promotional activity from competitors, is weighing on Albertsons' top-line outlook.
Albertsons said it faces intense price competition from peers including Walmart, Kroger and Amazon.com as those companies compete to provide more affordable grocery options to cost-conscious households. The company cited this competitive dynamic as a contributing factor to its lower sales guidance.
Financial results for the fourth quarter reflected those strains. The grocer reported a net loss of $480.8 million for the quarter, compared with a net profit of $171.8 million in the year-ago period. The swing was driven in part by charges related to opioid-related claims recorded during the quarter.
Separately, Albertsons announced it will pay $774 million to settle thousands of lawsuits filed by U.S. states, local governments and Native American tribes that allege its pharmacy operations helped fuel the national opioid crisis. The company said the payment is intended to resolve those claims.
The company's revised forecast and recent charges underscore the dual pressures of competitive discounting and constrained consumer spending in the grocery sector. Management's outlook for fiscal 2026 identical sales - flat to up 1% - falls short of the LSEG analyst average of a 1.58% gain.
Also included in recent communications was promotional material noting an external service that evaluates investment cases for ACI using automated methods, describing how that service assesses fundamentals, momentum and valuation across many companies. The company name and the service reference appear alongside Albertsons' investor-focused news but are not part of the firm's own operational guidance.
Summary
Albertsons cut its identical sales outlook for fiscal 2026 to flat to 1% growth, below the LSEG analyst average of 1.58%, as the grocer grapples with aggressive discounting from larger rivals and weaker shopper demand. The company posted a fourth-quarter net loss of $480.8 million versus a year-earlier profit of $171.8 million, and said it will pay $774 million to resolve thousands of opioid-related lawsuits.
Key points
- Albertsons expects fiscal 2026 identical sales to be flat to up 1%, below analysts' average of 1.58% according to LSEG.
- The grocer reported a fourth-quarter net loss of $480.8 million, compared with a $171.8 million profit a year earlier, after recording charges tied to opioid-related claims.
- Albertsons will pay $774 million to settle thousands of lawsuits by U.S. states, local governments and Native American tribes alleging its pharmacies contributed to the opioid epidemic.
Risks and uncertainties
- Ongoing legal and settlement costs related to opioid litigation could continue to affect profitability and cash flow for the company and weigh on the broader retail and pharmaceutical sectors.
- Intensified discounting by larger competitors such as Walmart, Kroger and Amazon.com may pressure gross margins and same-store sales in the grocery sector.
- Persistent inflation and economic uncertainty could keep consumers constrained, reducing overall demand for staples and impacting retailers dependent on discretionary and non-discretionary grocery sales.